SNA
56
3
GIS
47
13
D
32
10
HP
44
14
ED
39
8
MO
47
6
FMC
23
7
DOW
47
4
PX
56
3
TROW
37
8
FCX
44
4
CCL
68
6
GM
55
6
HUM
25
4
EFX
43
3
DRI
74
5
PPL
44
9
ALL
37
3
MPC
28
3
OKE
61
2
SNA
56
3
GIS
47
13
D
32
10
HP
44
14
ED
39
8
MO
47
6
FMC
23
7
DOW
47
4
PX
56
3
TROW
37
8
FCX
44
4
CCL
68
6
GM
55
6
HUM
25
4
EFX
43
3
DRI
74
5
PPL
44
9
ALL
37
3
MPC
28
3
OKE
61
2
Financhill
Back

Allogene Therapeutics 10K Form

Sell
4

ALLO
Allogene Therapeutics

Last Price:
$1.88
Seasonality Move:
0.51%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ALLO News And Ratings

See the #1 stock for the next 7 days that we like better than ALLO

ALLO Financial Statistics

Sales & Book Value

Annual Sales: $95K
Cash Flow: $-44.5M
Price / Cash Flow: 0
Annual Sales: $2.21
Price / Book: 0.85

Profitability

EPS (TTM): -1.56000
Net Income (TTM): $-283.4M
Gross Margin: --
Return on Equity: -52.73%
Return on Assets: -42.25%

Allogene Therapeutics Earnings Forecast

Key Allogene Therapeutics Financial Ratios

  • The Research & Development expenses have been 255,698.95% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • Per Share Earnings over the last 6 years have been positive in 3 years.

Allogene Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ALLO
CUSIP: 019770
Website: allogene.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 12.8
Quick Ratio: 12.46

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ALLO Technical Analysis vs Fundamental Analysis

Sell
4
Allogene Therapeutics (ALLO) is a Sell

Is Allogene Therapeutics a Buy or a Sell?